Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer.

Maryam Moradi BinabajFereshteh AsgharzadehFarzad RahmaniAbdulridha Mohammed Al-AsadyMilad HashemzehiAtena SoleimaniAmir AvanSaeedeh MehrabanElnaz GhorbaniMikhail RyzhikovMajid KhazaeiSeyed Mahdi Hassanian

Published in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2023)

This study demonstrating the potent anti-tumor effects of Vactosertib against CRC progression. Our results clearly suggest that this inhibitor could be a promising agent reducing CRC tumor progression when administered either alone or in combination with standard treatment in CRC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
combination therapy
replacement therapy